Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor CB-1158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Trial Profile

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor CB-1158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs CB 1158 (Primary) ; Nivolumab (Primary)
  • Indications Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 06 Jun 2017 Results (n=9) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 Results (n = 17) from this trial were presented at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO), according to a calithera Biosciences media release.
    • 05 Jun 2017 Results (n = 17) published in a Calithera Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top